PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Negative cost of revenue growth (cost reduction) can be positive but verify quality impact. Benjamin Graham would examine if cost cuts are sustainable.
12.50%
Gross profit growth 10-15% suggests moderate improvement. Benjamin Graham would check quality of earnings.
No Data
No Data available this quarter, please select a different quarter.
37.48%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
21.30%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
100.00%
Marketing expense growth above 10% signals aggressive spending. Seth Klarman would demand evidence of revenue impact.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
29.39%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-30.36%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Other expenses growth 0-15% reflects moderate increase. Benjamin Graham would investigate nature of expenses.
-30.95%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-30.95%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-22.58%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
7.95%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
7.95%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.